Werewolf Therapeutics Q2 FY26 swings to net income of $3.7 million; revenue rises to $21 million

• Werewolf Therapeutics swung to GAAP net income of USD 3.7 million, from a GAAP net loss of USD 18 million a year earlier.
• GAAP collaboration revenue rose to USD 21 million, driven by revenue recognized from the sale of its JZP898 program to Jazz.
• GAAP R&D expense fell 52.84% to USD 6.2 million, while GAAP G&A expense climbed 74.57% to USD 7.7 million.
• Cash and cash equivalents dropped to USD 22 million as of June 30, from USD 46.5 million as of March 31; runway forecast into Q2 2027.
• Werewolf repaid all amounts owed under its K2 loan agreement; CEO Daniel J. Hicklin expects H2 updates on strategic alternatives and WTX-124/WTX-330 data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Werewolf Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607310700PRIMZONEFULLFEED9801313) on July 31, 2026, and is solely responsible for the information contained therein.